drugset / Trial / NCT05456087

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087 ↗

Phase 2 Active not recruiting 20 enrolled Zel Skin and Laser Specialists Merz Aesthetics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not associated with scarring or other internal disease called 'pattern hair loss'. This type of hair loss is medically called 'androgenic or androgenetic alopecia'. In men it is typically called 'male pattern baldness' whereas in women it is called 'female pattern baldness' and in both cases is hereditary meaning there will be a history of relatives that describe having the same condition.

Timeline

Start
2022-08-12
Primary completion
2024-12
Completion
2024-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 150 iu Other

Indications